ABCL
AbCellera Biologics Inc.
Key Financials
Operating Income
$-217103000
↑ 31.0%
Revenue
$75.1M
↑ 160.6%
Net Income
$-146412000
↑ 10.1%
EPS (Diluted)
$-0.49
↑ 10.9%
Total Assets
$1.4B
↓ 0.3%
Total Liabilities
$390.0M
↑ 28.1%
Shareholders' Equity
$966.9M
↓ 8.4%
Cash & Equivalents
$128.5M
↓ 17.8%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 4 | 8/18/2026 | View on SEC |
| 4 | 8/14/2026 | View on SEC |
| 4 | 8/14/2026 | View on SEC |
| 8-K | 8/13/2026 | View on SEC |
| 424B5 | 8/13/2026 | View on SEC |
| 4 | 8/13/2026 | View on SEC |
| 424B5 | 8/11/2026 | View on SEC |
| 8-K | 8/10/2026 | View on SEC |
| 8-K | 8/7/2026 | View on SEC |
| 10-Q | 8/5/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | ABCL |
| Company Name | AbCellera Biologics Inc. |
| CIK | 1703057 |
| Sector | Pharmaceutical Preparations |
| Industry | Large accelerated filer |
| Exchange | Nasdaq |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | A1 |
| Phone | (604) 559-9005 |